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Abstract
Background: The introduction of C-C chemokine receptor type-5 (CCR5) antagonists as antiretroviral therapy has
led to the need to study HIV co-receptor tropism in different HIV-1 subtypes and geographical locations. This study
was undertaken to evaluate HIV-1 co-receptor tropism in the developing world where non-B subtypes
predominate, in order to assess the therapeutic and prophylactic potential of CCR5 antagonists in these regions.
Methods: HIV-1-infected patients were recruited into this prospective, cross-sectional, epidemiologic study from
HIV clinics in South Africa, Uganda and India. Patients were infected with subtypes C (South Africa, India) or A or D
(Uganda). HIV-1 subtype and co-receptor tropism were determined and analyzed with disease characteristics,
including viral load and CD4
+ and CD8
+ T cell counts.
Results: CCR5-tropic (R5) HIV-1 was detected in 96% of treatment-naïve (TN) and treatment-experienced (TE)
patients in India, 71% of TE South African patients, and 86% (subtype A/A1) and 71% (subtype D) of TN and TE
Ugandan patients. Dual/mixed-tropic HIV-1 was found in 4% of Indian, 25% of South African and 13% (subtype A/
A1) and 29% (subtype D) of Ugandan patients. Prior antiretroviral treatment was associated with decreased R5
tropism; however, this decrease was less in subtype C from India (TE: 94%, TN: 97%) than in subtypes A (TE: 59%;
TN: 91%) and D (TE: 30%; TN: 79%). R5 virus infection in all three subtypes correlated with higher CD4
+ count.
Conclusions: R5 HIV-1 was predominant in TN individuals with HIV-1 subtypes C, A, and D and TE individuals with
subtypes C and A. Higher CD4
+ count correlated with R5 prevalence, while treatment experience was associated
with increased non-R5 infection in all subtypes.
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Background
Human immunodeficiency virus type-1 (HIV-1) is char-
acterized by extensive genetic heterogeneity. Molecular
epidemiologic studies have demonstrated that globally,
the most prevalent forms of HIV-1 are subtypes (clades)
C, B and A [1-3]. Subtype C, which accounts for almost
50% of all HIV-1 infections globally, predominates in
sub-Saharan Africa and India [1-3]. Subtype B is the
main genetic form in the Americas, Australia and wes-
tern Europe; subtype A predominates in areas of central
and eastern Africa (Kenya, Uganda, Tanzania and
Rwanda) and in eastern Europe [1-3]; and subtype D is
distributed mainly in east Africa, including Uganda [1].
H I V - 1s u b t y p e sd i f f e rb ya sm u c ha s2 0 - 2 5 %a tt h e
genetic level [2], and have varying biological characteris-
tics, including differences in disease progression, patho-
genicity, transmissibility and co-receptor usage [1,2,4-7].
Studies of HIV-1 co-receptor tropism, which have
been conducted primarily in populations where subtype
B infections predominate, have demonstrated a relation-
ship between HIV-1 co-receptor use and disease stage.
In general, early stages of infection and disease are char-
acterized by greater prevalence of only C-C chemokine
type 5 (CCR5)-tropic (R5) HIV-1, which has been asso-
ciated with slower progression to AIDS [8-12]. The
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(CXCR4)-using virus (X4) has been associated with
greater treatment experience and higher risk of death,
and coincides with more rapid CD4
+ T-cell depletion
and disease progression [6,8,9,12,13]. Some variants of
HIV-1 can use either co-receptor (dual/mixed-tropic
[DM] HIV-1); these can be found in all stages of infec-
tion, but are more common in infections of longer dura-
tion, with lower CD4
+ cell counts and higher viral loads
[12-14]. Despite the emergence of X4-using variants in
some patients, only R5 infection typically persists in the
majority of patients. Nearly 50% of patients who die of
HIV-1 disease have only R5 HIV-1 detectable at the
time of their death, indicating that CCR5 remains a cri-
tical co-receptor throughout the course of HIV infection
[12,15].
Although HIV-1 co-receptor usage and its relationship
to disease stage have been studied in the developed
world, where subtype B predominates, such relationships
are less well understood for subtypes A, C and D. The
R5 phenotype is predominant in subtype C HIV-1 infec-
tions, whereas X4-using virus has been reported infre-
quently, even in advanced disease. R5-using virus is
more common in subtype A than subtype D HIV-1
infections, and a high proportion of subtype D infections
shows D/M tropism throughout the course of disease
[16-24]. However, some of these previous studies have
been limited by small sample sizes.
The introduction of the CCR5 antagonist, maraviroc,
for HIV-1 therapy [25] has increased interest in the epi-
demiology of tropism and relationships with HIV-1 sub-
type. A greater understanding of the tropism of non-B
s u b t y p eH I V - 1i sk e yf o rt h eo p t i m a lu s eo fC C R 5
antagonists in the treatment of these infections in the
developing world, and HIV-1 prevention strategies, such
as topical microbicides and systemic pre- or post-expo-
sure prophylaxis. In addition, this information will be
important for management of clinic populations in the
developed world that include individuals with non-B
subtype infections who have migrated from endemic
countries [26]. HIV-1 tropism can be determined by
genotypic and phenotypic methods. While genotypic
assays may have lower specificity and sensitivity, retro-
spective analyses have found that they are comparable
to phenotypic tropism assays for prediction of response
to treatment with CCR5 antagonists, in populations pre-
screened with a phenotypic assay [27,28].
The clinical development programme for maraviroc,
the first-in-class CCR5 antagonist, used the Trofile
®
phenotypic assay (Monogram Biosciences, South San
Francisco, California) [29-31], which determines tropism
via the expression of full-length env genes of multiple
viruses isolated from patient plasma and can detect 10%
of X4 variants with 100% sensitivity. More recently, a
Trofile
® assay with enhanced sensitivity to improve
detection of low-level X4-using variants has been devel-
oped that can detect 0.3% of these variants with 100%
sensitivity. Otherwise, assay validation performance
characteristics are equivalent between the original and
enhanced Trofile
® assays [31]. The enhanced Trofile
®
assay has been validated in a number of studies by re-
testing the co-receptor tropism of clinical samples that
were initially determined using the original assay
[31-34]: in a re-analysis of samples from the Phase 3
MERIT study, which evaluated the efficacy of maraviroc
in treatment-naïve patients with CCR5-tropic virus, 15%
of enrolled patients (n = 106/721) were reclassified as
having D/M virus with the enhanced assay [34].
The aim of this study was to estimate the prevalence
of R5-, D/M-, and X4-tropic HIV-1 among isolates
obtained from patients with HIV-1 subtype C infection
from India and South Africa, and with subtype A/A1
and D infection from Uganda, and to explore the demo-
graphic and clinical characteristics associated with R5
infection. In addition, the study examined the ability of
the Trofile
® assay to determine tropism of non-B sub-
types of HIV-1, which previously had not been explored
in a large study.
Methods
Study design
HIV-1-infected, antiretroviral therapy (ART) treatment-
naïve (TN) and treatment-experienced (TE) viremic
patients were recruited into this prospective, cross-sec-
tional, epidemiologic study from HIV clinics in South
Africa (four sites), Uganda (one site), and India (seven
sites) in 2007 and 2008. Sites were selected if they had
considerable experience with both HIV management
and HIV research. The study protocol was approved by
the institutional review board at each site.
Both TN and TE adults (aged 18 years or older) were
eligible for enrolment in India and Uganda. In South
Africa, where the MERIT study had previously been
conducted in TN patients [35], only TE adults were eli-
gible for inclusion in the present study. No patients
were recruited from any other study.
Patients who had received less than 10 days of ART
were considered to be TN; those who had experienced
failure of at least one three-drug ART regimen were
considered to be TE. To maximize the external validity
and generalizability of the study, only one member of a
known infection cluster (i.e., only one member of a
family affected by HIV) was eligible for enrolment.
Study procedure
At a single visit, the study was explained to patients, and
verbal and written informed consent were obtained
prior to conduct of any study procedures. Demographic,
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lected; blood was drawn and analyzed for CD4
+ and
CD8
+ T cells using BD FACS™ CAP (Becton Dickinson
and Company, Franklin Lakes, New Jersey), and for
HIV-1 RNA levels using Amplicor HIV-1 Monitor™
UltraSensitive Assay (Roche Diagnostics, Indianapolis,
Indiana).
For individuals with viral loads exceeding 500 copies/
mL, HIV-1 subtype was determined based on reverse
transcriptase and protease gene sequence (Monogram
Biosciences). Pol subtyping was performed by generating
three distinct sets of partial-length nucleotide sequences
from patient-derived reverse transcriptase and protease
genes. Genetic sequence comparison was determined by
the Basic Local Alignment Search Tool algorithm, and
subtype was resolved by a customized software package
that was validated against the publically available tool
on the National Center for Biotechnology Information
web site at the National Institutes of Health. Samples
determined to be HIV-1 subtypes of interest (A/A1 and
D in Uganda; C in South Africa and India) were further
tested for viral tropism.
HIV-1 co-receptor tropism was determined using the
original Trofile
® assay [29,30] for samples collected
from patients in South Africa and Uganda. The Indian
cohort was enrolled after the South African and Ugan-
dan cohorts, thus Indian patients were tested using the
newly available enhanced Trofile
® assay, which had
replaced the original assay. Samples were prepared for
both the original and enhanced assays in the same way:
1 mL plasma samples underwent centrifugation and
viral RNA was isolated, purified and subjected to poly-
merase chain reaction (PCR) amplification of the entire
HIV envelope gene (env). Co-transfection of HIV env
expression vectors and HIV-1 genomic vectors produced
pseudoviruses containing full length env genes derived
from patient virus populations. Tropism was determined
by measuring the ability of the pseudovirus population
to efficiently infect target cells co-expressing CD4 with
either the CXCR4 or CCR5 co-receptor [29,31].
For commercial Trofile
® testing, up to 3 mL of plasma
and up to three attempts at RNA PCR amplification are
performed for each patient specimen. For this study of
non-subtype B specimens, however, only a single
attempt at amplification was made with 1 mL samples
and primers that were optimized on subtype B speci-
mens (hereafter referred to as “standard primers”). In
the event that samples yielded a non-reportable tropism
result, re-testing was performed using modified primers
that were optimized for subtypes A, C and D but
retained high performance for subtype B (hereafter
referred to as “optimized primers”). All re-testing with
optimized primers was performed using the same ver-
sion of Trofile
® that was used for the initial 1 mL test.
Thus for South African and Ugandan specimens, all re-
testing was performed with the original assay, and for
Indian specimens, all re-testing was performed with the
enhanced assay.
Sample size and statistical analysis
The study goal was to include at least 171 patients with
reportable tropism results in each country, subtype and
treatment experience stratum to provide approximately
5% precision for estimating prevalence of R5 in TN
patients (anticipated to be 85%) and 7.5% precision for
estimating prevalence of R5 in TE patients (anticipated
to be 50%).
Demographic and HIV disease characteristics were
summarized by country, subtype and treatment experi-
ence strata. The prevalence of R5, X4, and D/M HIV-1
among patients with reportable tropism results was esti-
mated in each stratum. The relationship between R5
infection and the following variables was examined in
univariate logistic regression analyses: age (per year);
gender; CD4
+ cell count (per 50 cells/mm
3); HIV-1
RNA level (per 10,000 copies/mL); ART experience sta-
tus; time since HIV diagnosis (months); mode of trans-
mission; and Centers for Disease Control and
Prevention (CDC) HIV disease category. CD4
+ count
and HIV-1 RNA level were also analyzed using quartiles.
Variables significantly associated with tropism in uni-
variate analyses (p < 0.05) were entered into multivariate
logistic regression analyses, in which two-way interac-
tions between all covariates were examined categorically.
Backward elimination from a saturated model was used
to determine the final predictive model.
Results
Patients
The demographic and clinical characteristics of patients
with reportable HIV-1 tropism results are summarized
in Table 1. All but four patients in South Africa and
Uganda identified themselves as African: three self-iden-
tified as mixed race, and one as Caucasian. All but one
p a t i e n ti nI n d i a( w h os e l f - i d e n t i f i e da sA s i a n )i d e n t i f i e d
themselves as Indian. In all countries, nearly all patients
reported heterosexual contact as the mode of HIV
transmission.
Haemophilia/coagulation disorder and/or blood trans-
mission were reported as transmission factors by three
patients (1.5%) in South Africa and two patients (1.1%)
in India. Four patients (one in South Africa, one in
Uganda, and two in India) reported other unspecified
risk behaviours. Risk was not reported or identified by
21 patients (8.8%) in India, two patients (1.0%) in South
Africa, and one patient (0.9%) in Uganda. Most patients
in South Africa and Uganda were female; most Indian
patients were male.
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+ counts than
South African and Ugandan patients; however, mean
viral loads were consistent across the three countries
(Table 1). TE patients were more likely (53-79%) to
have CDC category C AIDS-defining events than TN
patients (12-42%), regardless of country (Figure 1).
Across treatment experience, the proportions of patients
with CDC category C HIV disease were higher in India
(79% of TE and 42% of TN patients) than in South
Africa or Uganda (Figure 1).
Subtype analysis
Samples for subtype analysis were collected from 307
patients (95 TE, 212 TN) in India, 678 (96 TE, 582 TN)
in Uganda, and 297 (all TE) in South Africa. All samples
with HIV-1 RNA exceeding 500 copies/mL were sub-
mitted for subtype testing. HIV-1 subtype could not be
determined in 2.9%, 2.4%, and 5.9% of samples from
India, Uganda, and South Africa, respectively, due to
samples compromised by collection or handling pro-
blems and/or atypical genetic sequences (inability to
Table 1 Demographics and clinical characteristics of patients with reportable tropism results
India South Africa Uganda
Subtype C
(N = 240)
Subtype C
(N = 205)
Subtype A/A1
(N = 236)
Subtype D
(N = 236)
TN
(n = 174)
TE
(n = 66)
TE
(n = 205)
TN
(n = 204)
TE
(n = 32)
TN
(n = 113)
TE
(n = 23)
Age: mean (SD) 36 (8.2) 39 (7.5) 37 (7.9) 38 (8.7) 38 (8.7) 35 (8.4) 33 (8.3)
Gender: % male 65% 82% 41% 32% 31% 35% 22%
Time since HIV diagnosis (months): mean (SD) 23 (36.2) 68.4 (43.7) 48.9 (31.5) 37.7 (35.4) 62.8 (48.1) 32.6 (26.6) 46.6 (19.0)
Number of treatment failures: mean (SD) NA 1.5 (1.6) 1.3 (0.58)* NA 1.2 (0.4) NA 1.0 (0.2)
Absolute CD4
+ cell count (cells/μL): mean (SD) 155.7 (128.5) 114.0 (110.1) 204.0 (146.1)* 334.3 (178.9) 83.4 (64.8) 361.0 (198.0) 109.3 (124.2)
CD4
+ count: range 3-775 6-504 1-681 5-1171 8-223 10-1255 1-589
Viral load (log10 copies/mL): mean (SD) 5.52 (5.46) 5.40 (5.42) 5.09 (5.55) 5.27 (5.33) 5.60 (5.20) 5.11 (5.19) 5.15 (5.22)
Log viral load: range 3.16-5.88 3.16-5.88 3.04-6.63 3.40-5.88 3.13-5.86 3.33-5.85 3.07-5.88
NA, not available; SD, standard deviation; TE, treatment-experienced; TN, treatment-naïve.* Missing 1; n = 204.
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Figure 1 Distribution of Centers for Disease Control and Prevention (CDC) human immunodeficiency virus disease category by
treatment experience, subtype, and country.
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sequence within the patient’s virus that is cleaved by the
restriction enzyme used in the assay). Recruitment of
TE patients with reportable tropism in Uganda and
India, where HIV treatment is limited, was a challenge
and required reducing the numbers of patients in these
strata. TN samples were submitted for subtyping up
until the enrolment goal of at least 171 patients had
been reached.
Subtype C was predominant in India (overall, 280
[91%]: 202 [95%] TN and 78 [82%] TE patients) and
South Africa (275 [93%] TE patients). The predominant
subtypes in Uganda were A/A1 (overall, 324 [48%]: 285
[49%] TN and 39 [41%] TE patients) and D (overall, 203
[30%]: 167 [29%] TN and 36 [38%] TE patients). Other
subtypes representing ≥ 1% of the Ugandan cohort were
A/D (8%), AE (2.4%), C (2.2%), and Complex (1.5%).
Tropism
Samples from patients with subtype C virus from India
and South Africa and subtypes A/A1 and D from
Uganda that were initially tested for co-receptor tropism
using a single 1 mL aliquot of patient plasma yielded
the following reportable results, respectively, when RNA
amplification was performed with the standard primers:
240 (86%), 205 (75%), 236 (81%) and 136 (67%) (Figure
2). After re-testing all South African, Ugandan and
Indian non-reportable samples using optimized primers
for RNA amplification, the reportable rate improved to
90-97% in the different strata.
Overall, most patients with reportable tropism results
had only R5 HIV-1, but the proportion with R5 virus
varied substantially by country, subtype and treatment
e x p e r i e n c e( F i g u r e3 ) .T h ep r o p o r t i o nw i t ho n l yR 5
virus ranged from 30% among TE Ugandan patients
infected with subtype D to 97% among TN Indian
patients infected with subtype C. D/M-tropic HIV-1 was
less frequent, ranging from 3% among TN subtype C-
infected patients in India to 65% among TE patients
from Uganda with subtype D infection. X4 HIV-1 was
rare and found in only eight TE patients from South
Africa, and in two TN subtype A-infected patients and
one TE subtype D-infected patient from Uganda.
Although co-receptor tropism varied according to
country in TE patients with subtype C infection, R5
tropism was consistently high in TN patients with sub-
type C. R5 tropism was identified in 97% of TN patients
with subtype C from India (Figure 3) and, in the MERIT
study of maraviroc [35], a similar analysis identified R5
tropism in 94% of 293 TN patients with subtype C, of
whom a large majority (92%) were South African.
Variables significantly associated with tropism appear
in Figure 4. Higher CD4
+ count was associated with an
increased likelihood of R5 tropism in patients from both
India and South Africa (Figures 4A and 4B). Addition-
ally, in South African patients, older age and higher
HIV-1 viral load predicted R5 tropism (Figure 4B).
Among Ugandan patients infected with subtype A/A1
HIV-1, higher CD4
+ counts were associated with R5
tropism and CDC category B disease was negatively
associated with R5 tropism (Figure 4C), whereas among
patients infected with subtype D, only higher CD4
+
counts predicted R5 tropism (Figure 4D).
Discussion
In this study, CCR5 was the predominant co-receptor
used in non-B subtype HIV-1 in ART-naïve individuals
from India and Uganda, and in TE individuals from
South Africa. In contrast to prior reports, this study
evaluated a large number (n = 817) of both TN and TE
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Figure 4 Multivariate model for covariates significantly associated with R5 virus. A. India subtype C (N = 238). B. South Africa subtype C (N
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were difficulties recruiting TE patients in India and
Uganda, which may indirectly reflect the availability of
ART, estimated by the World Health Organization to
reach only 31% of HIV-infected persons in these coun-
tries [36].
Most (83%) study subjects with reportable tropism
results had only R5 HIV-1 detectable, including 90% of
TN and 72% of TE patients. However, tropism distribu-
tion varied by subtype, CD4
+ cell count and treatment
experience, which can be considered a marker of
advanced disease. Indian subjects with subtype C virus
were almost exclusively infected with R5 regardless of
their CD4
+ count, HIV-1 disease status, or treatment
experience. The prevalence of R5 virus was similarly
high in TN South African patients with subtype C infec-
tion but, while most common and relatively well-pre-
served, was somewhat lower in the South African TE
cohort of this study (71%). The difference observed
between R5 prevalence in India and South Africa may
be a result of differences in CD4+ cell count. Compared
with the Indian cohort, there was a higher proportion of
individuals in the South African cohort with a D/M phe-
notype (25%) despite similar time since HIV diagnosis
and similar exposure to prior therapies. Exclusive use of
X4 was rare (4%).
Our findings are consistent with previous reports of
subtype C strains from India and elsewhere, where R5
HIV-1 is maintained even in advanced stages of disease.
For example, some similarities can be observed between
the findings of the present study and a previous study
that assessed co-receptor tropism of HIV-1 strains in
China: mainly that R5 tropism was seen exclusively in
subtype C infections, and remained stable over time
[24]. These data highlight the persistence of CCR5 trop-
ism even in long-term infections, possibly related to dif-
ferences within the env variable loops [37], and
contrasts with other subtypes, especially subtype B,
where X4 HIV-1 is more frequent during later stages of
infection [6,8-10,16,18,21,37-40].
The distribution of HIV-1 subtypes in India and
South Africa was consistent with published epidemio-
l o g i cd a t a[ 6 ] .H o w e v e r ,t h i ss t u d yf o u n dm o r es u b -
type diversity within the Ugandan cohort than
previously reported [41,42]. Despite the existence of
multiple subtype variations in Uganda, the predomi-
nant subtypes were A/A1 (49.0%) and D (28.7%), and
there were no marked differences in demographics or
HIV disease characteristics. Among Ugandan subjects
with subtype A/A1 virus, R5 infection predominated
in TN individuals but was reduced in TE individuals,
similar to the pattern seen with subtype B. While
subtype D TN patients were predominantly R5, X4-
using virus (D/M and X4) was detected in nearly 70%
of the small number of TE patients. This agrees with
earlier reports, where Ugandan individuals infected
with subtype D virus showed predominantly D/M
tropism [6,16-19,21,22].
Multivariate analyses of other cohorts have identified
higher CD4
+ cell count as a predictor of R5 infection in
both TN and TE patients with subtype B and C HIV-1
infections [43,44]. In the present study, multivariate ana-
lysis identified CD4
+ count as a significant predictor of
CCR5 tropism for subtypes C, A/A1, and D. In Ugandan
patients with subtype A/A1, R5 use was negatively asso-
ciated with the presence of CDC category B disease,
with a negative trend for category C.
This study provided an opportunity to assess the abil-
ity of the Trofile
® assay to provide results in different
non-B subtype HIV-1 viral subtypes collected in devel-
oping countries. While initial testing using standard
amplification primers with just a single 1 mL aliquot of
patient plasma yielded a lower reportable rate (67-86%)
than that expected from experience with subtype B
virus, non-reportable samples that were re-tested with
the original Trofile
® assay (South Africa and Uganda) or
enhanced assay (India) using modified primers opti-
mized for non-B subtype virus, yielded a much higher
percentage of reportable results (90-97%), and the distri-
bution of R5 and non-R5 HIV-1 did not change. These
improvements in amplification primers - which also
retain high performance for subtype B specimens and
are currently the primers used regularly for RNA ampli-
fication in the Trofile as s a y-m a yb ea d v a n t a g e o u s
when Trofile testing is used in clinical populations
where non-subtype B virus is common [45].
Globally, these data offer guidance on the potential
use of CCR5 antagonists and tropism tests in resource-
poor clinical settings. Since HIV transmission appears to
be mostly associated with R5 HIV-1 regardless of sub-
type [46-48] and a large majority of chronic HIV-1
infections in India and South Africa are R5, CCR5
a n t a g o n i s t sm a yh a v ear o l ei np r e v e n t i o ne f f o r t s :f o r
example, use as microbicides or in pre- and post-expo-
sure prophylaxis. Combining a CCR5 antagonist with
another ARV agent active against all or X4-using viruses
may improve the potential utility of CCR5 antagonists
in ARV-based HIV-1 prevention strategies. In the con-
text of evaluating patients for CCR5 antagonist therapy,
the high proportions of R5 HIV-1 in both TN (97%)
and TE (94%) patients in India suggests that alternative
methods for determining co-receptor status could be
explored in this setting. Tropism could potentially be
tested using genotypic or phenotypic co-receptor trop-
ism tests and/or virologic response to short-term CCR5
antagonist monotherapy.
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This study examined the correlates of HIV-1 co-recep-
tor tropism in virus from individuals with non-B sub-
type HIV-1 infection from India, Uganda and South
Africa. While only R5 virus was detectable in the major-
ity of TN individuals infected with subtypes C, A and D,
infection with only R5 virus was maintained, albeit at
lower levels, in TE individuals. However, R5 prevalence
varied by subtype: patients with subtype C, especially in
India, were almost exclusively infected with R5, while
subtype D patients were more frequently infected with
D/M viruses. The high prevalence of R5 HIV-1 in sub-
type C infections makes a CCR5 antagonist an attractive
option for ART-based prevention strategies in areas
where subtype C predominates. While a higher CD4
+
cell count was highly correlated with CCR5 use regard-
less of subtype, a further understanding of HIV-1 co-
receptor use in individuals and populations infected
with non-subtype B HIV-1 is still needed. Given the het-
erogeneity of HIV-1 co-receptor use in non-subtype B
HIV-1, there remains a need for prospective determina-
tion of HIV-1 tropism prior to the initiation of CCR5
antagonist therapy in geographic locations where the
burden of infection is greatest.
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